HK StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Nonprofit Pharmaceutical Companies

497.166

-8.909-1.76%

Number of Gainers:4

Number of Losers:27

Number of Flat:2

PE:- -

High:517.538

Open:506.335

Low:496.695

Close:506.075

Volume:76.92M

Turnover:2.19B

Market Cap:317.06B

Float Cap:282.96B

Loading ...

JD Health Releases 65 New Drugs in First Half, Leading the Industry and Expanding Its Dominance as China's Largest Online Pharmacy

Hong Kong Market Close August 13: Hang Seng Index Declines 0.17% as Tencent Slumps Over 4% Post-Earnings; Lenovo Surges 20% to Record High

A-Shares Market Close: Three Major Indices Retreat After Rally, CRO and Pharmaceutical Sectors Stage Strong Rebound

Shuozhou City Market Regulation Bureau Conducts Cross-Inspection of Medical Device Safety

Three Major Cross-Border Deals Land on Same Day, Boosting Sentiment for Chinese Innovative Drug Outbound Licensing; T+0 Huatai Baorui Hang Seng Innovative Drug ETF (520500) Attracts Over 2.5 Billion Yuan in Net Inflows Over the Past Year

China's Midday Market: Shanghai Composite Up 0.42%, ChiNext Rises 1.61% as Pharma and Computing Power Surge

Akeso's Ivonescimab Gets Third Indication Approval in China

MT Newswires Live

Medical Equipment Procurement Shows Sustained Monthly Recovery, Sector Valuations Poised for Rebound

Listing Update: Suzhou Zelgen Biopharmaceuticals Files Again for Hong Kong IPO

Akeso Says NMPA Approves Ivonescimab for 1L Treatment of SQ-NSCLC

Summit Gains After Partner Akeso Secures China Nod for Lung Cancer Combo

AKESO (09926) Gains NMPA Nod for Third Indication of Its First-in-Class Bispecific Antibody, Ivonescimab, in Frontline Squamous NSCLC

Akeso - Nmpa Approves Ivonescimab for 1L Treatment of Sq-Nsclc

THOMSON REUTERS

Akeso Says China NMPA Approves Ivonescimab Plus Chemo for First-Line Squamous NSCLC

Akeso - China Nmpa Approves Ivonescimab Plus Chemotherapy for First-Line Advanced Squamous Nsclc

THOMSON REUTERS

Three Emerging Export Sectors: How Many Does Nanjing Jiangbei New Area Command?

ACOTEC-B (06669) Warns of Mid-Year Net Loss Up to 80.9 Million Yuan, Reversing from Profit

Acotec Scientific Expects Net Loss of no More than RMB 80.9 Mln for HY

Acotec Scientific - Expects Net Loss of no More than Rmb80.9 Mln for Six Months Ended June 30, 2026

THOMSON REUTERS

Acotec Scientific - Expected Hy Result Due to One-Off Impairment Loss and Provision

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/stock/BK1574/news?page=11"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"BK1574","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","market":"HK","secType":"PLATE","nameCN":"Nonprofit Pharmaceutical Companies","latestPrice":497.16638,"timestamp":1787553009214,"preClose":506.0749,"halted":0,"volume":76920077,"delay":0,"changeRate":-0.017603,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Trading","change":-8.908508,"latestTime":"08-24 14:30:09","open":506.33536,"high":517.53845,"low":496.69476,"amount":2194421361,"amplitude":0.041187,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1787559000000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1787535000000,1787544000000],[1787547600000,1787558400000]],"pbRate":4.109535,"peRate":-81.157718,"turnoverRate":0.002791,"increases":4,"decrements":27,"flats":2,"marketCap":317060392240,"floatMarketCap":282962598744},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","high":517.53845,"amplitude":0.041187,"preClose":506.0749,"low":496.69476,"pbRate":"4.109535","latestPrice":497.16638,"volume":76920077,"delay":0,"open":506.33536,"prevYearClose":556.26263,"prevWeekClose":506.075,"prevMonthClose":473.313,"prevQuarterClose":453.519,"fiveDayClose":505.128,"twentyDayClose":497.839,"sixtyDayClose":520.536,"secType":"PLATE","market":"HK","turnoverRate":0.002791,"peRate":-81.157718,"marketCap":317060392240,"floatMarketCap":282962598744,"timestamp":1787553009214,"nameCN":"Nonprofit Pharmaceutical Companies"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1574\",,,,undefined,":{"bkCode":"BK1574","up":4,"down":27,"flat":2},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1574\",pageSize:20,pageCount:11,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1108533739","title":"JD Health Releases 65 New Drugs in First Half, Leading the Industry and Expanding Its Dominance as China's Largest Online Pharmacy","url":"https://stock-news.laohu8.com/highlight/detail?id=1108533739","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1108533739?lang=en_us&edition=fundamental","pubTime":"2026-08-13 16:52","pubTimestamp":1786611139,"startTime":"0","endTime":"0","summary":"JD Health (06618) reported a total revenue of RMB 40.9 billion for the first half of 2026, marking a 15.9% year-on-year increase. Under the Non-IFRS metric, its operating profit reached RMB 3.5...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1571","86618","BK1161","BK1515","BK1247","LU0051755006.USD","06618","09939","LU0456827905.SGD","SGXZ62798434.SGD","BK1142","159938","BK1591","BK1615","BK1574","BK1583","BK1589","SGXZ86797644.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1176927262","title":"Hong Kong Market Close August 13: Hang Seng Index Declines 0.17% as Tencent Slumps Over 4% Post-Earnings; Lenovo Surges 20% to Record High","url":"https://stock-news.laohu8.com/highlight/detail?id=1176927262","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1176927262?lang=en_us&edition=fundamental","pubTime":"2026-08-13 16:49","pubTimestamp":1786610991,"startTime":"0","endTime":"0","summary":"Hong Kong's three major stock indexes ended Tuesday's session with mixed results, as the Hang Seng Tech Index briefly rallied over 1% in the afternoon. The benchmark Hang Seng Index closed 0.17%...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0501845795.SGD","IE0008368742.USD","LU0873338254.USD","LU0651947912.USD","LU0049853897.USD","LU0611395673.USD","LU2148510915.USD","IE0031814852.USD","00992","ESPO","LU0708995153.HKD","SG9999003461.SGD","LU0880133367.SGD","LU0642271901.SGD","BK1618","LU2247934214.USD","LU0499858602.USD","LU0396098781.USD","SG9999017495.SGD","LU0107464264.USD","BK1526","LU1196710195.USD","LU2008162690.USD","LU0516422440.USD","BK4550","LU0210527791.USD","LU0862451753.SGD","LU1568876335.HKD","LU0080751232.USD","LU0878005551.USD","LU1188198961.HKD","LU2279701549.SGD","LU0048388663.USD","LU1770036033.HKD","SGXZ81514606.USD","LU0264606111.USD","LU0067412154.USD","LU0327786744.USD","LU0634319403.HKD","LU0370786039.SGD","LU1981816686.USD","LU2251237488.HKD","IE0001KFT4U8.USD","IE00BZ08YR35.GBP","IE00B0169N27.USD","LU0049112450.USD","LU0320764755.SGD","LU0070217475.USD","LU0348814723.USD","HTCD.SI","LU1048484197.HKD","LU0868486357.SGD","IE0008369823.USD","LU0594300419.USD","LU0675040207.SGD","LU2498475776.HKD","LU0244354667.USD","LU0543330566.HKD","LU0348783233.USD","513600","LU1831875114.USD","ODDS","LU0979878070.USD","TCEHY","LU0061477393.USD","LU0588545730.USD","LU0117844026.USD","LU0211977185.USD","LU1226287875.USD","LU1808992512.USD","BK1608","LU0054237671.USD","09115","LU0898667661.SGD","LU0293314216.USD","LU0577902454.USD","LU1794554557.SGD","LU0127658192.USD","LU0417516571.SGD","LU2242644610.SGD","LU2237443465.HKD","LU2106854487.HKD","LU1814569148.SGD","LU0289960550.SGD","SGXZ90724238.SGD","IE00B97KM107.HKD","LU0307460666.USD","LU1725190679.HKD","LU1951186391.HKD","80992","LU1439102457.SGD","LU1282649067.USD","SOCL","SG9999001093.SGD","SGXZ31699556.SGD","LU0211331839.USD","BK1588","03115","BK1544","LU0348825331.USD","IE00BGV7N243.SGD","LU0348788117.USD","LU0865486749.SGD","IE00B067MR52.USD","LU2125910500.SGD","LU1880383440.USD","LU1770034418.SGD","LU2462611646.USD","LU0577902611.USD","SGXZ99366536.SGD","LU1675838814.USD","BK1213","LU1868838027.USD","LU0348723411.USD","IE00B031J352.USD","HSI","LU0132412106.USD","LU2317271919.USD","SG9999007991.SGD","LU1242518931.SGD","LU2051468812.USD","LDEM","LU0315178854.USD","LU0541501648.USD","LU1868837722.USD","LU0856984785.SGD","SG9999014674.SGD","LU0431992006.USD","LU0516422952.EUR","LU1515016050.SGD","LU2399975544.HKD","LU0228367735.SGD","LU1769817096.USD","LU3227948356.SGD","HK0001040143.USD","LU0786609619.USD","LU1282649810.SGD","LU0516423174.USD","LU0229945570.USD","LU0345769631.USD","LU0384037296.USD","LU1917777945.USD","LU0315179316.USD","LU1211504680.USD","LU1303224171.USD","LU0828238088.HKD","BK4585","LU1960683339.HKD","LU1044875133.USD","LU1044874839.SGD","IE0003851619.USD","LU2294711473.HKD","LU0456842615.SGD","03330","LU0096374516.USD","07500","SG9999015986.USD","HK0000306701.USD","LU1226287529.USD","LU0828237510.HKD","LU0890818403.SGD","LU0052750758.USD","LU0054450605.USD","IE00B0169L03.USD","LU1769817179.HKD","LU1785774172.SGD","LU0345769128.USD","LU0441854154.USD","LU1720050803.USD","LU2023250504.SGD","LU0149534421.HKD","LU1008478684.HKD","LU1323998911.USD","LU1226288253.USD","LU2152927971.USD","IE00B0JY6N72.USD","IE00B3M56506.USD","LU0593848301.USD","LU0594300179.USD","LU2362540622.SGD","MCHmain","SG9999001051.SGD","LU0128522157.USD","LU0469268626.HKD","LU2097828631.EUR","LU0149721374.USD","BK4504","LU0106252389.USD","LU2087589342.USD","HK0000151867.HKD","LU0819123356.HKD","LU1688375341.USD","MHImain","IE00BPRC5H50.USD","LU0417516902.SGD","LU1504937902.USD","LU1051769294.HKD","BK1591","LU0048597586.USD","VXUS","LU0882747503.HKD","LU0235996351.USD","LU2476274308.USD","LU0449509016.USD","LU2097828714.EUR","BKF","GB00BDT5M118.USD","LU1568876251.USD","SG9999001226.SGD","LU0589944569.HKD","LU0648948544.HKD","IE00BZ08YS42.EUR","03037","LU2097828557.USD","BK1521","LU0651946864.USD","LU1282651048.USD","LU1051768304.USD","LU0541502299.USD","LU1282649141.HKD","AAXJ","LU0210533765.USD","LU1328615791.USD","LU1868837565.USD","LU0708995583.HKD","LU0047713382.USD","LU0633140727.USD","LU0531970944.HKD","IE00BF5LJ272.USD","LU2237443978.SGD","LU0608807433.USD","LU1226288097.SGD","EMC","LU2778985437.USD","LU1048588211.SGD","LU2097828805.USD","SG9999015978.USD","LU0164872284.USD","LU1328277881.USD","LU0918141705.HKD","LU0823426308.USD","SG9999013353.USD","LU0784639295.USD","07300","IE0003895053.USD","LU0261950983.USD","LU1642822792.SGD","LU2097828474.EUR","SG9999014880.SGD","SG9999000327.SGD","LU0287142896.SGD","LU0328353924.USD","LU0588545490.SGD","SG9999018865.SGD","LU0261947096.USD","LU0502904849.HKD","LU0821914370.USD","LU0143863784.USD","LU0326948709.USD","LU2125910849.SGD","LU1226287792.SGD","IEMG","LU0414403682.SGD","LU2257852520.SGD","LU2476274720.SGD","LU1961090484.USD","LU0456846285.SGD","LU0605514214.HKD","LU0791590937.USD","LU0214875030.USD","LU0072913022.USD","LU0463099449.HKD","SG9999018857.SGD","LU0700851271.USD","LU0738912210.USD","LU0164865239.USD","BK1610","HK0000914660.USD","LU0488056044.USD","LU1733274390.USD","LU1993786604.SGD","IE00BQXX3C00.GBP","LU1734074674.USD","LU0320764599.SGD","LU1719994722.HKD","LU0320764243.SGD","LU0359202008.SGD","LU0640798160.USD","00325","LU0175139822.USD","LU1316542783.SGD","LU1282648689.USD","LU0203345920.USD","LU0188438112.USD","SG9999006597.SGD","LU1813983027.USD","SGXZ51526630.SGD","LU0862451837.USD","IE0003795394.USD","LU0918141887.USD","LU1226288170.HKD","LU2362541273.HKD","LU0039217434.USD","LU1064130708.USD","SG9999001903.USD","LU2279858448.HKD","LU0348735423.USD","LU0359201885.HKD","LU2237443382.USD","LU1224444064.USD","03419","LU0029874905.USD","LU0048580855.USD","LU0543330483.HKD","LU1267930227.SGD","IE00B031HY20.USD","LU0359201612.USD","LU0072462343.USD","BK1095","BK1586","LU0192582467.USD","LU2362541513.USD","LU1115378108.SGD","LU0173614495.USD","LU1064131003.USD","LU0823038988.USD","LU0588546209.SGD","LU1439103000.SGD","LU0572939691.SGD","SG9999000459.SGD","LU1883866441.USD","LU0683595622.HKD","LU1366334651.USD","02833","KWEB","LU0259732245.USD","LU0737861772.HKD","LU1152091754.HKD","LU0084288322.USD","LU1046422090.SGD","LU0348827113.USD","BK1574","FFEM","TCHmain","LU1807302812.USD","LU0163747925.USD","LU2133065610.SGD","BK1589","02800","LU0254981946.USD","LU0269904917.USD","LU0029875118.USD","BK1609","SG9999004220.SGD","LU0348805143.USD","HHImain","LU0672654166.SGD","LU0823413587.USD","EEMX","LU1282651121.HKD","LU1718418525.SGD","IE0034224299.USD","HK0000352291.HKD","SG9999001846.SGD","LU0608807946.USD","JADE","LU2045819591.USD","LU3063872942.SGD","LU1974910355.USD","LU0516422366.SGD","IE00B29SXG58.USD","LU0106959298.USD","SG9999001069.SGD","SG9999014898.SGD","EMCS","LU0228659784.USD","LU0140636845.USD","SG9999015952.SGD","LU0607220059.USD","LU2237443622.USD","LU2265009873.SGD","LU0165289439.USD","SG9999014906.USD","BK4581","LU0456827905.SGD","LU0572940350.SGD","LU0128522744.USD","LU1655091459.SGD","LU0823413660.USD","KCAI","LU0823397103.USD","LU0737861699.HKD","BK1592","BK1531","LU0823040885.USD","LU1102505762.USD","LU0348784397.USD","LU1235295612.USD","LU0052756011.USD","LU1481107354.HKD","BK1607","LU0531971595.HKD","LU0577902298.EUR","LU0588545904.SGD","JEMA","LU0181495838.USD","LU0455707207.USD","LU2226246903.HKD","00700","LU1105468828.SGD","LU0210526637.USD","BIDD","BK1161","LU0117841782.USD","LNVGY","LU0797268264.HKD","BK1502","IE00B031HW06.USD","IE0009570106.USD","LU0540923850.HKD","LU0985320562.USD","07200","HK0001040168.HKD","SG9999006514.SGD","LU0043850808.USD","LU0203347892.USD","LU2488822045.USD","LU0823397285.USD","HK0000320223.HKD","IE0032834883.USD","LU2293587155.HKD","IE0032431581.USD","LU0011963245.USD","IE00BQXX3F31.USD","LU0329678170.USD","LU1196710351.USD","LU0572944931.SGD","LU1880383366.USD","BK4588","LU0823039010.USD","IE00BQXX3D17.EUR","09688","LU0169518387.USD","LU0577902538.SGD","BK1198","82800","LU0128525689.USD","IE00B543WZ88.USD","LU2177674079.SGD","HK0000352382.USD","SG9999015945.SGD","LU1196710864.SGD","LU1804176565.USD","LU1102505929.USD","LU1171460220.USD","LU1810669033.SGD","LU2449936058.SGD","LU0326950275.SGD","CXSE","LU1048596156.SGD","FDNI","LU1366334578.USD","LU0329678337.USD","LU0831103253.SGD","LU0972618739.USD","LU0878004406.USD","LU0819121731.USD","LU0828237940.HKD","SG9999002828.SGD","LU2039709279.SGD","LU0348816934.USD","LU2251237306.USD","LU0314109678.HKD","LU0871576103.HKD","TCHI","HK0000914686.HKD","IE0008368411.USD","LU1251922891.USD","LU0164880469.USD","LU0417516738.SGD","HSImain","LU0106259558.USD","LU0509642566.USD","LU1152091168.USD","HK0000306685.HKD","SG9999002463.SGD","LU2237443895.HKD","IE00B5MMRT66.SGD","BK1516","LU0310800965.SGD","LU0823041008.USD","EDZ","LU2237443549.SGD","XSOE","HK0000320264.USD","LU0633140560.USD","LU0449515922.USD","LU1691799644.USD","LU0791591158.USD","LU0345775950.USD","LU1242518857.USD","IE00B8HQ1Z84.USD","LU0348783662.USD","LU1044876610.USD","LU1733274473.HKD","LU0886674414.USD","LU0561508036.HKD","BK1615","LU0251144936.SGD","LU1224709979.USD","LU0345776255.USD","83115","SG9999002562.SGD","SG9999014914.USD","LU1956131251.USD","SG9999000418.SGD","LU0196878994.USD","SG9999001689.USD","LU0051755006.USD","IE00BZ08YT58.USD","BK1517","LU0499858438.USD","IE00B8L5B284.USD","LU0231483743.USD","LU0143863198.USD","LU0577902371.SGD","LU1023057109.AUD","BK1193","LU0650527681.SGD","LU0823426480.USD","LU0516423091.SGD","GAMR","LU1629966141.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1118756885","title":"A-Shares Market Close: Three Major Indices Retreat After Rally, CRO and Pharmaceutical Sectors Stage Strong Rebound","url":"https://stock-news.laohu8.com/highlight/detail?id=1118756885","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1118756885?lang=en_us&edition=fundamental","pubTime":"2026-08-13 15:28","pubTimestamp":1786606106,"startTime":"0","endTime":"0","summary":" On August 13, the three major A-share indices experienced a pullback after an initial rally, closing the session in negative territory. By the end of trading, the Shanghai Composite Index settled at...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["159982","BK1574","BK1161","159938","09939","399300","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1163427165","title":"Shuozhou City Market Regulation Bureau Conducts Cross-Inspection of Medical Device Safety","url":"https://stock-news.laohu8.com/highlight/detail?id=1163427165","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1163427165?lang=en_us&edition=fundamental","pubTime":"2026-08-13 13:50","pubTimestamp":1786600255,"startTime":"0","endTime":"0","summary":"Shuozhou City Market Regulation Bureau has recently intensified oversight of medical device quality and safety across the entire supply chain, from distribution to clinical use. The initiative aims...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MDEV","HART","BK1100","BK1583","BK1574","PTH","LNGR","IEIH","RSPH","09996","GDOC","MEDX","159883","AGNG","LGHT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1146180327","title":"Three Major Cross-Border Deals Land on Same Day, Boosting Sentiment for Chinese Innovative Drug Outbound Licensing; T+0 Huatai Baorui Hang Seng Innovative Drug ETF (520500) Attracts Over 2.5 Billion Yuan in Net Inflows Over the Past Year","url":"https://stock-news.laohu8.com/highlight/detail?id=1146180327","media":"Deep News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1146180327?lang=en_us&edition=fundamental","pubTime":"2026-08-13 13:10","pubTimestamp":1786597841,"startTime":"0","endTime":"0","summary":"After years of sustained R&D investment, China's innovative drug industry is gradually moving past the early stage of heavy spending and profit pressure, with the profit realization capability of the...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MEDX","06978","LNGR","IBBQ","159992","BD","520500","BK1161","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1197662897","title":"China's Midday Market: Shanghai Composite Up 0.42%, ChiNext Rises 1.61% as Pharma and Computing Power Surge","url":"https://stock-news.laohu8.com/highlight/detail?id=1197662897","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1197662897?lang=en_us&edition=fundamental","pubTime":"2026-08-13 11:59","pubTimestamp":1786593583,"startTime":"0","endTime":"0","summary":"China's three major stock indexes opened higher on August 13 and then fluctuated, with heavyweight stocks lifting the indices. However, declining stocks outnumbered advancing ones, highlighting a...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","399300","159938","159982","BK1515","000688.SH","000905.SH","000300.SH","000001.SH","399001","09939","510300","510880","512880","159967","399006","512510","BK1161","515890"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659049182","title":"Akeso's Ivonescimab Gets Third Indication Approval in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2659049182","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659049182?lang=en_us&edition=fundamental","pubTime":"2026-08-13 10:36","pubTimestamp":1786588580,"startTime":"0","endTime":"0","summary":"Akeso  said ivonescimab has been approved in China for a third indication, according to a Wednesday filing with the Hong Kong Exchange.The approval covers the use of ivonescimab in combination with chemotherapy as a first-line treatment for patients with squamous non-small cell lung cancer .This marks the third major authorization for an ivonescimab-containing regimen in China since the molecule's initial approval in May 2024.The drug was previously approved in May 2024 for EGFR-mutated locally advanced or metastatic non-squamous NSCLC patients who progressed after EGFR TKI treatment, and in April 2025 as a first-line treatment for locally advanced or metastatic NSCLC with PD-L1-positive expression.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IE00BPRC5H50.USD","LU1961090484.USD","LU0417516902.SGD","LU2488822045.USD","LU0348827113.USD","BK1574","IE00B543WZ88.USD","LU0417516571.SGD","LU0561508036.HKD","IE00B5MMRT66.SGD","LU2778985437.USD","LU0348825331.USD","LU2476274308.USD","LU0417516738.SGD","LU1794554557.SGD","BK1161","LU1720050803.USD","LU0348783233.USD","LU2399975544.HKD","LU0634319403.HKD","LU2476274720.SGD","LU0348766576.USD","LU0348735423.USD","LU0540923850.HKD","09926","LU0348784397.USD","KURE","LU0348767384.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1128373791","title":"Medical Equipment Procurement Shows Sustained Monthly Recovery, Sector Valuations Poised for Rebound","url":"https://stock-news.laohu8.com/highlight/detail?id=1128373791","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1128373791?lang=en_us&edition=fundamental","pubTime":"2026-08-13 07:18","pubTimestamp":1786576706,"startTime":"0","endTime":"0","summary":"GTHT has released a research report noting that the ongoing implementation of equipment renewal policies is expected to drive long-term increases in medical equipment procurement levels. The...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0188","AGNG","601211","GDOC","MDEV","LGHT","CZA","REVS","BK0184","BK1574","BK0012","RSPH","09996","LCO","BK0201","BK0183","159883","IEIH","HART","NIFE","BK1100","BK1147","MEDX","BK0276","LNGR","02611","PTH","BK1564","BK0028","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1166586489","title":"Listing Update: Suzhou Zelgen Biopharmaceuticals Files Again for Hong Kong IPO","url":"https://stock-news.laohu8.com/highlight/detail?id=1166586489","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1166586489?lang=en_us&edition=fundamental","pubTime":"2026-08-13 06:35","pubTimestamp":1786574109,"startTime":"0","endTime":"0","summary":"The Hong Kong Stock Exchange disclosed on August 12 that Suzhou Zelgen Biopharmaceuticals Co., Ltd. (ticker: 688266.SH) has submitted a listing application to the main board, with CICC serving as the...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","01477","688266","BK1574","HEXmain","BK0239","IPOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659904569","title":"Akeso Says NMPA Approves Ivonescimab for 1L Treatment of SQ-NSCLC","url":"https://stock-news.laohu8.com/highlight/detail?id=2659904569","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659904569?lang=en_us&edition=fundamental","pubTime":"2026-08-13 01:47","pubTimestamp":1786556839,"startTime":"0","endTime":"0","summary":"BRIEF-Akeso Says NMPA Approves Ivonescimab For 1L Treatment Of SQ-NSCLCAug 12 (Reuters)-Akeso Inc9926.HK:NMPA APPROVES IVONESCIMAB FOR 1L TREATMENT OF SQ-NSCLCFurther company coverage:9926.HK","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nFWN4491E1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0348827113.USD","LU0417516738.SGD","LU2399975544.HKD","LU0634319403.HKD","KURE","LU1961090484.USD","LU2476274720.SGD","LU2778985437.USD","LU0348825331.USD","LU0417516902.SGD","LU0540923850.HKD","LU0348783233.USD","LU0348767384.USD","LU0561508036.HKD","LU1794554557.SGD","BK1574","LU2476274308.USD","09926","IE00B5MMRT66.SGD","LU0348735423.USD","LU2488822045.USD","IE00BPRC5H50.USD","LU1720050803.USD","LU0417516571.SGD","IE00B543WZ88.USD","BK1161","LU0348766576.USD","LU0348784397.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658908461","title":"Summit Gains After Partner Akeso Secures China Nod for Lung Cancer Combo","url":"https://stock-news.laohu8.com/highlight/detail?id=2658908461","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658908461?lang=en_us&edition=fundamental","pubTime":"2026-08-12 21:42","pubTimestamp":1786542133,"startTime":"0","endTime":"0","summary":"BUZZ-Summit gains after partner Akeso secures China nod for lung cancer combo** Shares of Summit TherapeuticsSMMT.Orise 3% to $15.58** Co says its partner Akeso9926.HKannounced the marketing authoriza","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nL4N44913L:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0540923850.HKD","LU1720050803.USD","LU2488822045.USD","LU0417516571.SGD","KURE","BK1161","LU0634319403.HKD","LU0417516738.SGD","LU1794554557.SGD","LU0348767384.USD","09926","LU0348825331.USD","SMMT","LU0348783233.USD","LU2399975544.HKD","IE00BPRC5H50.USD","LU0348735423.USD","LU0348827113.USD","IE00B543WZ88.USD","LU2778985437.USD","LU0348784397.USD","IE00B5MMRT66.SGD","BK4139","LU0348766576.USD","LU2476274308.USD","LU0561508036.HKD","LU1961090484.USD","BK1574","LU0417516902.SGD","LU2476274720.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1147433388","title":"AKESO (09926) Gains NMPA Nod for Third Indication of Its First-in-Class Bispecific Antibody, Ivonescimab, in Frontline Squamous NSCLC","url":"https://stock-news.laohu8.com/highlight/detail?id=1147433388","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1147433388?lang=en_us&edition=fundamental","pubTime":"2026-08-12 21:11","pubTimestamp":1786540312,"startTime":"0","endTime":"0","summary":"AKESO (09926) has announced that its independently developed, globally first-in-class bispecific antibody, Ivonescimab (marketed as Yidaifang®), has received approval from the China National Medical...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0561508036.HKD","IE00BPRC5H50.USD","BK1574","BK1161","09926","LU1169589451.USD","LU1961090484.USD","IPOS","LU0348784397.USD","IE00B543WZ88.USD","LU2476274308.USD","LU0348766576.USD","LU1720050803.USD","BK4023","PD","LU0540923850.HKD","LU0348783233.USD","LU1794554557.SGD","LU0417516738.SGD","LU0348735423.USD","LU2778985437.USD","LU0417516902.SGD","IE00B5MMRT66.SGD","KURE","LU1169590202.USD","LU0348825331.USD","LU2476274720.SGD","LU2399975544.HKD","LU0348827113.USD","LU0348767384.USD","LU0417516571.SGD","LU0634319403.HKD","LU2488822045.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658970884","title":"Akeso - Nmpa Approves Ivonescimab for 1L Treatment of Sq-Nsclc","url":"https://stock-news.laohu8.com/highlight/detail?id=2658970884","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658970884?lang=en_us&edition=fundamental","pubTime":"2026-08-12 20:52","pubTimestamp":1786539149,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nFWN4491E1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IE00B5MMRT66.SGD","LU0540923850.HKD","IE00BPRC5H50.USD","BK1161","LU0348783233.USD","LU0348827113.USD","IE00B543WZ88.USD","LU0417516738.SGD","LU0348766576.USD","LU0348825331.USD","09926","LU1720050803.USD","LU0348784397.USD","LU0417516571.SGD","LU0634319403.HKD","LU2476274720.SGD","LU0348735423.USD","BK1574","LU2488822045.USD","LU2778985437.USD","LU2399975544.HKD","KURE","LU0348767384.USD","LU2476274308.USD","LU1961090484.USD","LU1794554557.SGD","LU0417516902.SGD","LU0561508036.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658972050","title":"Akeso Says China NMPA Approves Ivonescimab Plus Chemo for First-Line Squamous NSCLC","url":"https://stock-news.laohu8.com/highlight/detail?id=2658972050","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658972050?lang=en_us&edition=fundamental","pubTime":"2026-08-12 20:22","pubTimestamp":1786537330,"startTime":"0","endTime":"0","summary":"Akeso says China NMPA approves ivonescimab plus chemo for first-line squamous NSCLCChina’s NMPA cleared ivonescimab with chemotherapy for first-line advanced squamous non-small cell lung cancer.Phase ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nNDL7SlDKQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2488822045.USD","LU0348766576.USD","LU0348783233.USD","LU1961090484.USD","LU0561508036.HKD","LU2476274720.SGD","LU1720050803.USD","LU0348784397.USD","LU0540923850.HKD","IE00BPRC5H50.USD","LU2399975544.HKD","LU2778985437.USD","IE00B5MMRT66.SGD","LU2476274308.USD","LU0417516738.SGD","BK1161","LU0348735423.USD","LU0348827113.USD","LU0417516571.SGD","BK1574","IE00B543WZ88.USD","LU1794554557.SGD","09926","LU0348825331.USD","LU0634319403.HKD","KURE","LU0348767384.USD","LU0417516902.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658997273","title":"Akeso - China Nmpa Approves Ivonescimab Plus Chemotherapy for First-Line Advanced Squamous Nsclc","url":"https://stock-news.laohu8.com/highlight/detail?id=2658997273","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658997273?lang=en_us&edition=fundamental","pubTime":"2026-08-12 20:18","pubTimestamp":1786537113,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nFWN44916C:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IE00BPRC5H50.USD","BK1161","LU0540923850.HKD","LU0417516902.SGD","LU0417516571.SGD","LU0348784397.USD","LU2488822045.USD","LU0348783233.USD","LU0561508036.HKD","LU0348766576.USD","LU1961090484.USD","LU0348825331.USD","LU2476274720.SGD","LU0348827113.USD","LU1794554557.SGD","LU1720050803.USD","09926","LU0348767384.USD","LU0348735423.USD","LU0634319403.HKD","LU2778985437.USD","LU0417516738.SGD","IE00B5MMRT66.SGD","LU2476274308.USD","IE00B543WZ88.USD","KURE","BK1574","LU2399975544.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1133654525","title":"Three Emerging Export Sectors: How Many Does Nanjing Jiangbei New Area Command?","url":"https://stock-news.laohu8.com/highlight/detail?id=1133654525","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1133654525?lang=en_us&edition=fundamental","pubTime":"2026-08-12 19:32","pubTimestamp":1786534358,"startTime":"0","endTime":"0","summary":"A fresh term, \"new-new three sectors,\" has recently gained traction in trade discussions. You may be familiar with the \"old three sectors\"—apparel, furniture, and home appliances—and the \"new three...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KOMP","CHAT","ROBO","AIFD","AIBU","LNGR","MEDX","06978","ARTY","BK1574","BK1161","PBOT","AGIX","QTOC","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1132439598","title":"ACOTEC-B (06669) Warns of Mid-Year Net Loss Up to 80.9 Million Yuan, Reversing from Profit","url":"https://stock-news.laohu8.com/highlight/detail?id=1132439598","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1132439598?lang=en_us&edition=fundamental","pubTime":"2026-08-12 18:28","pubTimestamp":1786530504,"startTime":"0","endTime":"0","summary":"ACOTEC-B (06669) has issued a profit warning, projecting a net loss of no more than 80.9 million yuan for the six months ending June 30, 2026. This marks a sharp reversal from the net profit of...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06669","BK1587","BK1574","BK1100"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658237976","title":"Acotec Scientific Expects Net Loss of no More than RMB 80.9 Mln for HY","url":"https://stock-news.laohu8.com/highlight/detail?id=2658237976","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658237976?lang=en_us&edition=fundamental","pubTime":"2026-08-12 18:25","pubTimestamp":1786530330,"startTime":"0","endTime":"0","summary":"BRIEF-Acotec Scientific Expects Net Loss Of No More Than RMB 80.9 Mln For HYAug 12 -Acotec Scientific Holdings Ltd6669.HK:EXPECTS NET LOSS OF NO MORE THAN RMB80.9 MLN FOR SIX MONTHS ENDED JUNE 30, 2026EXPECTED HY RESULT DUE TO ONE-OFF IMPAIRMENT LOSS AND PROVISIONFurther company coverage:6669.HK","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nFWN4490QA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1587","BK1574","06669","BK1100"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658997617","title":"Acotec Scientific - Expects Net Loss of no More than Rmb80.9 Mln for Six Months Ended June 30, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2658997617","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658997617?lang=en_us&edition=fundamental","pubTime":"2026-08-12 18:22","pubTimestamp":1786530160,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nFWN4490QA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1100","06669","BK1574","BK1587"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658764859","title":"Acotec Scientific - Expected Hy Result Due to One-Off Impairment Loss and Provision","url":"https://stock-news.laohu8.com/highlight/detail?id=2658764859","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658764859?lang=en_us&edition=fundamental","pubTime":"2026-08-12 18:22","pubTimestamp":1786530160,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nFWN4490QA:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1100","BK1587","BK1574","06669"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":14,"pageCount":11,"totalSize":279,"code":"91000000","status":"200"}]}}